Paul Peter Tak

Alma materVrije Universiteit Amsterdam
Leiden University
Scientific career
FieldsImmunology, gene therapy, bioelectronics
InstitutionsCandel Therapeutics
Kintai Therapeutics
GlaxoSmithKline

Paul-Peter Tak M.D. PhD FMedSci is an immunologist and academic specialising in the fields of internal medicine, rheumatology and immunology. Tak has been the President & CEO of Candel Therapeutics since September 2020.

Life and career

Tak graduated with a medical degree cum laude from the Amsterdam University Medical Centers and began his medical career as a practitioner in the Bronovo Hospital, The Hague. He joined Leiden University Medical Centre as a Fellow in Internal Medicine in 1990 and was awarded a Fellowship in Rheumatology in 1995. Tak received his PhD from Leiden University in 1996 for his thesis Immunohistologic studies of rheumatoid synovial tissue. He worked as a Clinical Associate Professor of Medicine at the University of California, San Diego, and next served as Professor of Medicine and Chair of the Department of Clinical Immunology & Rheumatology at Amsterdam UMC.[1]

Tak has studied the role of the vagus nerve in chronic inflammation, work which provided the basis for clinical trials exploring bioelectronics as a novel therapeutic approach in rheumatoid arthritis patients. He is also known for his studies on synovial biopsy and synovial tissue analysis. In his academic life, Tak has been Visiting Professor, William Harvey Research Institute (London), Honorary Senior Visiting Fellow (University of Cambridge), Honorary Professor of Rheumatology (Ghent University) and was elected a Fellow of the Academy of Medical Sciences (U.K.) in 2016.[2][3][4]

He was elected by peers as "Best Rheumatologist" in the Netherlands in 2011, and received the Medal of Honour of the Netherlands Society for Rheumatology the same year. He was rated as one of the world’s top 3 doctors in the field of rheumatoid arthritis by Expertscape in 2014.[5][6][7]

From 2011 to 2018, Tak worked at GlaxoSmithKline as Senior Vice President, Chief Immunology Officer and Global Development Leader. He was also the Chair of the Scientific Review Board. In 2018, Tak cofounded Sitryx Therapeutics with researchers Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum. Tak was appointed as Board Director of Levicept in July 2018. Tak was chief executive at Tempero Pharmaceutical, which was acquired by GlaxoSmithKline, then served as Chief Executive Officer at Kintai Therapeutics in 2018. He was also a venture partner at Flagship Pioneering. In September 2020, Tak became president and CEO of Candel Therapeutics and, in July of the following year, led the company to an Initial Public Offering (IPO) on the Nasdaq. In 2021, Tak was named as one of most inspiring people in life sciences on the PharmaVOICE100 list. Tak was included in The Medicine Maker Power List 2023 as one of the top ten leaders in the Biopharmaceuticals category. In March 2023, Tak was appointed Chair of the Board of Directors at Citryll.[8][9][10][11]

Publications

Tak has an h-index of 144 according to Google Scholar.[12] His publications include:

References

  1. "Paul Peter Tak | Precision Medicine". www.terrapinn.com. 17 May 2018. Retrieved 3 August 2018.
  2. Tak, Professor Paul-Peter (December 2017). "Interview with Paul-Peter Tak: Stimulating the vagus nerve to treat rheumatoid arthritis". Bioelectronics in Medicine. 1 (1): 17–20. doi:10.2217/bem-2017-0012. ISSN 2059-1500.
  3. "ACR Annual Meeting" (PDF). American College of Rheumatology. November 2012. Retrieved 7 August 2018.
  4. "Professor Paul-Peter Tak | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 8 August 2018.
  5. "Mednet Topartsen 2010". Mednet (in Dutch). 4 (1): 6–15. January 2011. doi:10.1007/s12462-011-0006-8. ISSN 1568-7716. S2CID 195312669.
  6. "Prizes". NVR Nederlandse Vereniging voor Reumatologie (in Dutch). Retrieved 10 August 2018.
  7. Expertscape. "Expertscape Ranks World's Top Doctors and Hospitals in Rheumatoid Arthritis". PRLog. Retrieved 10 August 2018.
  8. Eaton, Elizabeth. "Tak leaves GSK to join Flagship". Biocentury.com. Retrieved 31 January 2019.
  9. "GlaxoSmithKline Scientist Steps Down to Join Flagship Pioneering". Business Leader. 7 February 2019. Retrieved 8 February 2019.
  10. "Ex-GSK immunology chief takes over oncolytic virus biotech Candel as it ramps up its pipeline". FierceBiotech. 9 December 2020. Retrieved 17 March 2021.
  11. Al Idrus, Amirah. "Ex-GSK Shingrix chief Pfefer lands at Flagship as its 2nd CEO-Partner". FierceBiotech. Retrieved 30 October 2020.
  12. "Paul Peter Tak". Google Scholar. Retrieved 27 September 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.